Jupiter Topco LLC Acquires Shares of 24,500 AxoGen, Inc. $AXGN

Jupiter Topco LLC acquired a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 24,500 shares of the medical equipment provider’s stock, valued at approximately $1,132,000.

Several other institutional investors have also modified their holdings of the company. Lisanti Capital Growth LLC acquired a new position in shares of AxoGen during the 2nd quarter worth about $4,183,000. Stephens Investment Management Group LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $5,043,000. Edmond DE Rothschild Holding S.A. purchased a new stake in AxoGen during the second quarter worth approximately $1,469,000. Legato Capital Management LLC purchased a new stake in AxoGen during the fourth quarter worth approximately $1,323,000. Finally, SummitTX Capital L.P. acquired a new position in AxoGen in the first quarter valued at approximately $7,769,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Joseph A. Tyndall sold 3,500 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total transaction of $173,950.00. Following the transaction, the director owned 10,650 shares in the company, valued at approximately $529,305. This trade represents a 24.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 98,503 shares of company stock worth $4,656,947. 2.44% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on AXGN shares. Zacks Research upgraded shares of AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Citigroup restated a “market outperform” rating on shares of AxoGen in a research report on Thursday, July 30th. Jefferies Financial Group restated a “buy” rating and issued a $55.00 target price on shares of AxoGen in a report on Wednesday, July 29th. Truist Financial started coverage on shares of AxoGen in a research report on Wednesday, August 26th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, HC Wainwright lifted their price target on shares of AxoGen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

AxoGen Price Performance

Shares of NASDAQ:AXGN opened at $48.28 on Friday. AxoGen, Inc. has a one year low of $15.27 and a one year high of $52.91. The stock has a market capitalization of $2.60 billion, a price-to-earnings ratio of -71.00 and a beta of 1.16. The company has a 50-day simple moving average of $45.21 and a 200-day simple moving average of $40.05. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.12. The firm had revenue of $69.73 million for the quarter, compared to analysts’ expectations of $67.10 million. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. On average, analysts predict that AxoGen, Inc. will post -0.45 EPS for the current year.

AxoGen Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.